TRIB TRINITY BIOTECH PLC IFRS
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31
Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2018Q2*2018-06-30 | 2017Q2*2017-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $25.00M | $25.45M |
| Cost of revenue | $14.19M | $14.63M |
| Gross profit | $10.81M | $10.82M |
| R&D expense | $1.42M | $1.32M |
| SG&A expense | $7.36M | $7.56M |
| Operating income | $1.73M | $1.83M |
| Interest expense | $1.16M | $1.17M |
| Pretax income | $764,000 | $859,000 |
| Income tax | $158,000 | $176,000 |
| Net income | $594,000 | $902,000 |
| EPS (basic) | 2.80 | 4.10 |
| EPS (diluted) | 6.70 | 6.80 |
| Weighted avg. shares (diluted) | 26.16M | 27.10M |
| Balance sheet | ||
| Cash & equivalents | $49.43M | $63.98M |
| Receivables | $23.14M | — |
| Inventory | $34.82M | — |
| Current assets | $108.67M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $7.77M | — |
| Total assets | $194.45M | — |
| Current liabilities | $20.80M | — |
| Total liabilities | $127.75M | — |
| Shareholders' equity | $66.69M | — |
| Cash flow statement | ||
| Operating cash flow | $1.74M | $3.37M |
| Financing cash flow | -$3.88M | -$3.19M |
| Stock-based compensation | $329,000 | $130,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.